Zhen Li - 24 Sep 2026 Form 4 Insider Report for ADARx Pharmaceuticals, Inc. (ADRX)

Reporting relationship: President and CEO, Director, 10%+ Owner
Issuer ticker: ADRX
Reported as of: 24 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Sep 2026, 16:30:17 UTC
Source filing: View source filing
Reporting owner signature: /s/ Jiang Bian, Attorney-in-Fact

Key filing fact

Zhen Li filed Form 4 for ADARx Pharmaceuticals, Inc. (ADRX) on 28 Sep 2026.

Key facts

This page summarizes Zhen Li's Form 4 filing for ADARx Pharmaceuticals, Inc. (ADRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Sep 2026, 16:30.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001729510 Primary reporting owner

Li Zhen

Relationship: President and CEO, Director, 10%+ Owner
Address: C/O ADARX PHARMACEUTICALS, INC., 5871 OBERLIN DRIVE, SUITE 200, SAN DIEGO
Signature: /s/ Jiang Bian, Attorney-in-Fact
Signature date: 28 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADRX transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +1,024,152
Change %
Price: $0.000000^*
Shares after: 1,024,152
Date: 24 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,024,152
Exercise price: $17.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/4th of the total shares vest and become exercisable on September 24, 2027 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.